GoodRx Surpasses $500 Million in Savings For Diabetic Americans
GoodRx Surpasses $500 Million in Savings For Diabetic Americans
Over 2.5 million consumers with diabetes have found leading prescription savings and information via GoodRx
SANTA MONICA, Calif.–(BUSINESS WIRE)–GoodRx is a leading resource for people with diabetes to find prescription savings and information, having helped almost 2.5 million Americans save more than $500 million on diabetes treatments to date. By offering invaluable access to affordable diabetes medicines and glucose monitors, accurate and digestible information about treatment options, and thorough research on diabetes and insulin prices, GoodRx is making it easier for people to afford their medications and adhere to their treatment plans.
Diabetes is one of the most common chronic diseases in the U.S., affecting over 37 million people. For those who rely on insulin, being able to access and afford it is critical to their health and can quickly become a “life or death” emergency if not administered in a timely manner. While there are recent efforts to curb the prices of insulin, GoodRx Research shows the average cash price for insulin rose 54 percent from 2014 to 2019, and only decreased 7.1 percent from 2020 to 2023. And despite a bit of relief on insulin costs, there’s a significant economic burden that comes with a diabetes diagnosis. The cost of diabetes can exceed $5,800 per year when factoring in medications, doctor visits, outpatient care, and self-care to control blood glucose levels.
“It’s incredibly important that people with diabetes take their insulin as scheduled and don’t miss any doses,” said Sharon Orrange, MD, MPH, Director of Wellness, Preventative Care at the Ellison Institute for Transformative Medicine and Medical Advisor to GoodRx. “An individual with Type 1 diabetes will get sick within 24 hours without insulin and likely require hospitalization within 48 hours. Making insulin affordable for the millions of Americans who suffer from diabetes is essential to helping ensure their long term health.”
An internal analysis* on top diabetes treatments found consumers using GoodRx saved an average of:
- 86% on Pioglitazone
- 78% on Metformin and Metformin ER
- 69% on Glipizide ER
- 40% on insulin, including Insulin Glargine, Insulin Lispro and Insulin Aspart
- 37% on continuous glucose monitors, including Dexcom G6, Dexcom G7, FreeStyle Libre, FreeStyle Libre 2, and FreeStyle Libre 3
Top savings on diabetes treatments available through GoodRx include:
- An exclusive discount of $200 or more every month to self-pay customers not using insurance for the Dexcom G7 Transmitter/Sensor and Dexcom G6 CGM System.
- The Mounjaro Savings Card enables consumers to pay as little as $25 for a 1-month or 3-month prescription when presented to the pharmacist.
While cost is a significant barrier to diabetes patients accessing the care they need, a lack of clear, concise information about treatment plans can be a barrier as well. To help people with diabetes better understand their condition and treatment options, GoodRx Health empowers readers with answers to pressing questions so they can get healthy, stay healthy and actively participate in their health. The GoodRx Health Diabetes Center provides information about treatments, medications, common concerns, and more that is credible and up-to-date to support readers with actionable next steps for managing their condition. Each article is researched and written by a team of editorial experts, and clinical content is reviewed by a team of medical experts that includes physicians, pharmacists, and more.
“Managing a chronic condition can be incredibly expensive and time consuming – so much so, we’ve seen the cost of supplies and prescriptions used to manage diabetes impact which treatment plan patients opt for,” said Karla Robinson, MD, Medical Editor at GoodRx. “By providing incredible savings and information in one place, GoodRx is an invaluable resource for those living with diabetes to help them more easily access and afford the proper treatment they need.”
To find savings and trusted health information, download the GoodRx app or go to www.goodrx.com.
For even greater savings on your prescriptions, try GoodRx Gold. The monthly healthcare membership that can save you thousands, with over 1,000 drugs available under $10 and licensed healthcare provider visits starting at just $19.
*Based on July 2023 data
GoodRx is a leading resource for healthcare savings and information that makes healthcare affordable and convenient for all Americans. We offer consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. Since 2011, we have helped consumers save over $60 billion and are one of the most downloaded medical apps over the past decade.
GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding consumer savings and the benefits of our offerings to consumers. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits, changes in medication pricing and pricing structures, our reliance on a limited number of industry participants, the competitive nature of our industry, risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cyber-security and the important factors discussed in the sections entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, and our other filings with the Securities and Exchange Commission. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Business Partnerships Contact